Researchers at Stanford Medicine and the Gladstone Institutes will use the gift for gene editing and stem cell techniques to develop treatments for the neurodegenerative disorder.
May 4, 2017
The donation will support the first efforts to use gene editing and stem cell therapies to ameliorate Huntington’s disease, a progressive, inherited neurodegenerative disease that lacks approved drugs to slow its progress and for which there is no cure.
The research team is composed of Matthew Porteus, MD, PhD, associate professor of pediatrics at Stanford, who will lead the work; Frank Longo, MD, PhD, professor of neurology at Stanford; and Steve Finkbeiner, MD, PhD, of the Gladstone Institutes’ Taube-Koret Center for Neurodegenerative Disease Research. The team will also collaborate with clinical efforts at the UCSF Memory and Aging Center.
Tad Taube, founder and chairman of Taube Philanthropies, has contributed to research on neurodegenerative diseases in the past.
Approximately 30,000 people in the United States now have symptoms of Huntington’s disease, and another 200,000 people are at risk of developing it.
Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.